Public Company

HCW Biologics


HCW Biologics is a clinical-stage company advancing the development of novel immunotherapeutics designed to disrupt the link between chronic, low-grade inflammation and age-related disorders. This field, known as inflammaging, targets the unresolved inflammatory responses and chronic, low-grade inflammation associated with advancing age and believed to be a significant contributing factor to cancer and several chronic conditions, including cardiovascular disease, diabetes, neurodegenerative disease, and autoimmune disease. The core of HCW’s discovery and development efforts revolves around the company’s internally developed Tissue FactOr-Based FusIon (TOBI™) platform, which is designed to engineer multi-functional fusion protein molecules and protein complexes. The technology employs a Tissue Factor (TF) scaffold that can be packaged with multiple protein targets, including cytokines, chemokines, ligands, receptors, and single-chain antibodies, carefully selected to work in tandem to stimulate and target desired immune responses and inhibit unwanted inflammation.


Founded 2018
Type Public
Location Miramar, Florida, USA


HCWB $2.08 0.73% $0.02

Latest News

HCW Biologics Enters CRADA with National Cancer Institute Dec 08, 2022 GlobeNewswire Inc. NCI Activated as Clinical Site for Phase 1b/2 Clinical Trial to Evaluate HCW9218 in Advanced Pancreatic Cancer NCI Activated as Clinical Site for Phase 1b/2...
HCW Biologics is Granted Second Fundamental Patent: U.S. Patent for Multi-Chain Chimeric Polypeptide Created with TOBI™ Platform Dec 07, 2022 GlobeNewswire Inc. Allowed Claims for Novel Immunotherapeutic Compound Constructed with Tissue Factor as Platform for Target Binding Domains
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2022 Nov 08, 2022 Benzinga Upgrades For SolarEdge Technologies Inc (NASDAQ:SEDG), Northland Capital Markets upgraded the previous rating of Underperform to Market Perform. In the third quarter, SolarEdge Technologies showed...
Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation From the Phase 1 Clinical Trial to Evaluate HCW9218 in Solid Tumors At the SITC 37th Annual Meeting Nov 08, 2022 GlobeNewswire Inc. Presentation includes data on safety and dosage escalationand immune system reaction to HCW9218
HCW Biologics Reports Third Quarter 2022 Financial Results And Recent Business Highlights Nov 07, 2022 GlobeNewswire Inc. MIRAMAR, Fla., Nov. 07, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering...